Early Economic Evaluation

The model conservatively excludes disability pension, presenteeism, and post-acute coronary syndrome sick leave costs, all of which would increase the magnitude of projected savings. The model applies a one-year time horizon for intervention costs and a 0% discount rate because the treatment cycle takes under one year. Sensitivity analyses test insomnia remission scenarios of 25%, 50%, 75%, and 100% to capture uncertainty in treatment effectiveness. DRG-based cost estimates used in the model are internally valid for the Norwegian setting but have limited generalisability to other health systems. Productivity loss in the model is calculated using a conservative human capital approach that accounts for task transfers and overtime, likely underestimating true savings. The early HTA framework allows stakeholders to gauge economic value before full randomised controlled trial data are available, potentially shortening the path to implementation.